2,177 reports of this reaction
1.3% of all EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE reports
#17 most reported adverse reaction
RENAL IMPAIRMENT is the #17 most commonly reported adverse reaction for EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE, manufactured by Gilead Sciences, Inc. There are 2,177 FDA adverse event reports linking EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE to RENAL IMPAIRMENT. This represents approximately 1.3% of all 167,978 adverse event reports for this drug.
Patients taking EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE who experience renal impairment should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
RENAL IMPAIRMENT is a less commonly reported adverse event for EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE, but still significant enough to appear in the safety profile.
In addition to renal impairment, the following adverse reactions have been reported for EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE:
The following drugs have also been linked to renal impairment in FDA adverse event reports:
RENAL IMPAIRMENT has been reported as an adverse event in 2,177 FDA reports for EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE. This does not prove causation, but indicates an association observed in post-market surveillance data.
RENAL IMPAIRMENT accounts for approximately 1.3% of all adverse event reports for EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE, making it a notable side effect.
If you experience renal impairment while taking EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.